Argitalpenak (16) Ikertzaileren baten partaidetza izan duten argitalpenak

2024

  1. Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma

    Haematologica

  2. Correction to: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review (Blood Cancer Journal, (2024), 14, 1, (24), 10.1038/s41408-023-00966-9)

    Blood Cancer Journal

  3. Factor XI inhibitors: A new era in antithrombotic therapy

    Medicina Clinica

  4. Immunothrombosis: A key mechanism in the COVID-19 pandemic

    Medicina Clinica

  5. Impact of treatment effect on MRD and PFS: an aggregate data analysis from randomized clinical trials in multiple myeloma

    Blood Advances

  6. Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study

    HemaSphere

  7. Not so natural, not so killers

    Blood

  8. RASping myeloma genomics

    Blood

  9. Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma

    American Journal of Hematology

  10. Rate of recurrence after discontinuing anticoagulation in patients with venous thromboembolism within 30 days after COVID-19 vaccine

    European Journal of Clinical Investigation

  11. Real-World Data on Therapies for Relapsed or Refractory Multiple Myeloma: Key Data from ASH 2023—A Podcast

    Advances in Therapy

  12. Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia

    Blood Advances

  13. Targeting metalloproteases is a promising strategy to enhance immunotherapy responses by overcoming immune exclusion in hepatocellular carcinoma

    Gut

  14. The liver as a cytokine factory working on mRNA blueprints for cancer immunotherapy

    Cancer Cell

  15. Unveiling the multifaceted antitumor effects of interleukin 33

    Frontiers in Immunology

  16. Validation of mutated CEBPA bZIP as a distinct prognosis entity in acute myeloid leukemia: a study by the Spanish PETHEMA registry

    Haematologica